$147 Million Verdict Exposes Dangerous Monopoly in Medical Devices

In a striking blow to one of the world’s largest healthcare giants, Johnson & Johnson’s Biosense Webster has been ordered to pay $147 million in damages to Innovative Health, a company specializing in reprocessed cardiac medical equipment. The verdict follows a six-year legal battle that shed light on allegedly monopolistic tactics in the high-stakes electrophysiology market.

At the heart of the lawsuit was the Carto3 cardiac mapping system. Innovative Health claimed J&J effectively forced hospitals to purchase only brand-new, original catheters if they wanted access to the company’s clinical support. This left FDA-cleared reprocessed devices out of the equation, despite their lower cost and environmental benefits.

J&J argued that its practices were in place to protect patient safety and ensure device integrity. They likened the bundled system to needing shoelaces with shoes—inseparable. But on May 16, a California jury unanimously disagreed, ruling that J&J had violated federal and state antitrust laws through illegal tying and exclusivity arrangements.

This case is now considered one of the most significant antitrust judgments in the medical device sector. Advocacy groups like AMDR quickly applauded the decision, urging hospitals to remain vigilant against tactics that threaten market fairness and suppress cost-effective alternatives.

Johnson & Johnson has not yet issued a formal response to the ruling, but legal experts anticipate a possible appeal.